ABSTRACT
INTRODUCTION

25
Chagas disease (CD), caused by the parasite Trypanosoma cruzi (T. cruzi), is one of the main 26 health problems in Latin America. T. cruzi infection has been declared as a major public health 27 issue in the region, affecting approximately 6 to 7 million people worldwide. Bolivia is the 28 country with the highest prevalence and incidence of CD. In addition, travel and immigration 29 patterns have increased the relevance of T. cruzi infection outside of endemic areas [1] [2] [3] . 
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However, since it was a particular intervention, its long-term effect could not be measured. 
CONCLUSIONS
292 Overall, our findings suggest that Bolivian Pharmacovigilance system still presents some 293 challenges that should be addressed in the next years in order to achieve a strong, integrated 294 and consolidated ADR reporting system. The reinforcement of the Bolivian Pharmacovigilance 295 system is an ambitious project that should take a long-term perspective and several steps.
296
Continuity and perseverance are essential to achieve a solid and integrated reporting of ADR 297 system. UNIMED's current approach is to strengthen Bolivian Pharmacovigilance System in all 298 care levels, focusing on other neglected and prevalent pathologies in Bolivia and including all 299 the departments of the country. Several of our proposals are already in the process of being implemented. However, the responsibility of leading these actions is still unclear. Further 301 projects are needed in order to achieve a strong and consolidated ADR reporting system to 
